

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/559,982
				Filing Date	February 2, 2006
				First Named Inventor	Ruggero Fariello
				Group Art Unit	1617
				Examiner Name	Sahar JAVANMARD
Confirmation No.	6583				
Attorney Docket No.	373987-011US (102895)				
Sheet	1	of	1		

U.S. PUBLISHED DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Publication Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	A1				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>2</sup>	
		Office	Number	Kind Code (if known)			Yes	No
	B1							

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>2</sup>	
			Yes	No
	C113	Caccia <i>et al.</i> , "Safinamide: from molecular targets to a new anti-Parkinson drug," <i>Neurology</i> 67 (suppl. 2):S18-S23 (2006)		
	C114	Meshram <i>et al.</i> , "Safinamide as add-on to levodopa improves motor function without worsening dyskinesia in patients with mid-late Parkinson's disease," Poster 359, Movement Disorder Society 14th International Congress, Buenos Aires, Argentina, 13-17 June 2010.		
	C115	Rascol <i>et al.</i> , "A 2-year, multicenter, placebo-controlled, double-blind, parallel group study of the effect of riluzole on Parkinson's disease progression," <i>Movement Disorders</i> , 17 (Suppl. 5), S29 (2002)		
	C116	Borgohain <i>et al.</i> , "Effect of safinamide on depressive symptoms in patients with mid-late stage Parkinson's disease," Poster 324, Movement Disorder Society 14th International Congress, Buenos Aires, Argentina, 13-17 June 2010 ("Borgohain")		

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.